CD30 Inhibitors
1 drugsAbout CD30
CD30 (TNFRSF8) is a transmembrane receptor protein found on activated lymphocytes and malignant cells, particularly in lymphomas. It belongs to the tumor necrosis factor receptor superfamily. Its expression patterns make it a therapeutic target.
CD30 is a valuable drug target despite the lack of genetic evidence directly linking it to specific diseases. Its presence on malignant cells makes it a compelling focus for therapeutic intervention in CD30-expressing conditions.
CD30 is targeted by one FDA-approved drug, ADCETRIS (brentuximab vedotin), an antibody-drug conjugate (ADC). ADCETRIS, developed by SEATTLE GENETICS, is approved for 6 indications in the 'other' therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Non-small Cell Lung Cancer with only 2 trials.
- phase3 represents biological uncertainty with 50% completion.
Top Drugs
SEATTLE GENETICS is the only company with an approved drug targeting CD30.
High market concentration indicates potential entry barriers but also significant unmet need.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CD30, using adc modality.
Explore alternative modalities to differentiate from existing therapies and expand market reach.
Clinical Trials 175 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 60 | 39 | 14 | 6 | 74% |
| Phase 2 | 88 | 38 | 14 | 36 | 73% |
| Phase 3 | 19 | 7 | 2 | 9 | 78% |
| Phase 4 | 8 | 4 | 1 | 3 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved CD30 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting CD30. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2011 - 2011)
ADCETRIS was first approved in 2011 and remains the only approved drug.
The lack of recent approvals suggests a saturated market or challenges in developing new CD30-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 111 clinical trials targeting CD30.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities